Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.